Cizumab 100mg (Bevacizumab)

Cizumab is an antineoplastic agent whose active ingredient is bevacizumab. It belongs to the class of monoclonal antibodies and is used as part of targeted therapy for various malignant neoplasms.

MECHANISM OF ACTION

Bevacizumab is a recombinant human monoclonal antibody that specifically binds to vascular endothelial growth factor A (VEGF-A). By blocking VEGF, it prevents its interaction with receptors on the surface of endothelial cells, thereby inhibiting angiogenesis (formation of new blood vessels). This leads to regression of tumor vasculature, slowing tumor growth and metastasis.

INDICATIONS

• Metastatic colorectal cancer (in combination with chemotherapy)
• Locally advanced, recurrent, or metastatic non-small cell lung cancer
• Recurrent or therapy-resistant ovarian, fallopian tube, or primary peritoneal cancer
• Persistent, recurrent, or metastatic cervical cancer

IMPORTANT RISKS

Cizumab use is associated with an increased risk of:

• Gastrointestinal (GI) perforation
• Severe hemorrhage (including pulmonary and cerebral)
• Arterial and venous thromboembolic events (e.g., myocardial infarction, stroke, pulmonary embolism)
• Severe hypertension
• Impaired wound healing

Contraindicated in patients with active bleeding or GI perforation.

DOSING REGIMEN

The dose varies by indication but typically ranges from 5 to 15 mg/kg of body weight, administered intravenously every 2 or 3 weeks.

• First infusion: 90 minutes
• Subsequent infusions: 30–60 minutes if well tolerated

Pre-infusion hydration and blood pressure monitoring are mandatory.

CONTRAINDICATIONS

• Hypersensitivity to bevacizumab or any excipient
• Active bleeding of any origin
• Gastrointestinal perforation
• Severe, uncontrolled arterial hypertension

ADVERSE EFFECTS

Common: Hypertension, fatigue, headache, proteinuria, epistaxis, diarrhea, abdominal pain
Serious: GI perforation, thromboembolic events, impaired postoperative wound healing

SPECIAL WARNINGS AND PRECAUTIONS

• Therapy must be administered exclusively in specialized oncology centers.
• Before each infusion, blood pressure, renal function, and presence of bleeding must be assessed.
• Do not administer within 28 days after surgery.
• Contraindicated during pregnancy—may cause fetal developmental abnormalities.

STORAGE CONDITIONS

• Store infusion solution in a refrigerator at 2°C to 8°C.
• Do not freeze.
• Opened vials or prepared solutions may be used within 24 hours if stored refrigerated.

DISCLAIMER

Cizumab is a potent antineoplastic agent and should be used only under the supervision of an oncologist in a certified medical facility. The information provided on mhp.ooo is for reference purposes only and must not be construed as medical advice or a treatment guide. Self-treatment of oncological diseases is life-threatening.